Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity

被引:19
|
作者
Lundstrom, K
Hawcock, AB
Vargas, A
Ward, P
Thomas, P
Naylor, A
机构
[1] GLAXO WELLCOME RES & DEV LTD,MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND
[2] GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND
关键词
Semliki Forest virus system; tachykinin NK1 receptor; mutagenesis; site-directed; binding assays; functional coupling;
D O I
10.1016/S0014-2999(97)01226-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Molecular modelling and site-directed mutagenesis were used to identify eleven amino acid residues which may be involved in antagonist binding of the human tachykinin NK1 receptor. Recombinant receptors were expressed in mammalian cells using the Semliki Forest virus system. Wild type and mutant receptors showed similar expression levels in BHK and CHO cells, verified by metabolic labelling Binding affinities were determined for a variety of tachykinin NK1 receptor antagonists in SFV-infected CHO cells. The binding affinity for GR203040, CP 99,994 and CP 96,345 was significantly reduced by mutant Q165A. The mutant F268A significantly reduced the affinity for GR203040 and CP 99,994 and the mutant H197A had reduced affinity for CP 96,345. All antagonists seemed to bind in a similar region of the receptor, but do not all rely on the same binding site interactions. Functional coupling to G-proteins was assayed by intracellular Ca2+ release in SFV-infected CHO cells. The wild type receptor and all mutants except A162L and F268A responded to substance P stimulation. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 50 条
  • [31] ANTINOCICEPTIVE ACTIVITY OF THE TACHYKININ NK1 RECEPTOR ANTAGONIST, CP-99,994, IN CONSCIOUS GERBILS
    RUPNIAK, NMJ
    WEBB, JK
    WILLIAMS, AR
    CARLSON, E
    BOYCE, S
    HILL, RG
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (02) : 1937 - 1943
  • [32] Stress-induced increase of cortical dopamine metabolism:: attenuation by a tachykinin NK1 receptor antagonist
    Hutson, PH
    Patel, S
    Jay, MT
    Barton, CL
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 484 (01) : 57 - 64
  • [33] Delayed NK1 tachykinin receptor antagonist treatment reduces ICP following stroke in an Ovine model
    Sorby-Adams, A.
    Leonard, A.
    Thornton, E.
    Hunter, D.
    Turner, R.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 210 - 210
  • [34] NK1, NK2 and NK3 tachykinin receptor localization and tachykinin distribution in the ileum of the mouse
    Vannucchi, MG
    Faussone-Pellegrini, MS
    ANATOMY AND EMBRYOLOGY, 2000, 202 (03): : 247 - 255
  • [35] NK1, NK2 and NK3 tachykinin receptor localization and tachykinin distribution in the ileum of the mouse
    M. -G. Vannucchi
    M. -S. Faussone-Pellegrini
    Anatomy and Embryology, 2000, 202 : 247 - 255
  • [36] Effect of the long-acting tachykinin NK1 receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets
    Khan, S
    Liu, YC
    Khawaja, AM
    Manzini, S
    Rogers, DF
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (01) : 189 - 196
  • [37] IN-VITRO AND IN-VIVO EVIDENCE FOR A TACHYKININ NK1 RECEPTOR ANTAGONIST EFFECT OF VAPREOTIDE, AN ANALGESIC CYCLIC ANALOG OF SOMATOSTATIN
    BETOIN, F
    ADVENIER, C
    FARDIN, V
    WILCOX, G
    LAVARENNE, J
    ESCHALIER, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 279 (2-3) : 241 - 249
  • [38] NK1 antagonist
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1997, 2 (04) : 162 - 162
  • [39] Aprepitant and L-758298 -: Antiemetic -: Antidepressant -: Tachykinin Nk1 antagonist
    Sorbera, LA
    Castañer, J
    Bayés, M
    Silvestre, J
    DRUGS OF THE FUTURE, 2002, 27 (03) : 211 - 222
  • [40] Casopitant Mesilate. Tachykinin NK1 antagonist, Treatment of nausea and vomiting
    Owen, R. T.
    Serradell, N.
    Bolos, J.
    Castaner, R.
    DRUGS OF THE FUTURE, 2008, 33 (09) : 737 - 744